Recruiting
Early Phase 1

Cannabidiol

Sponsor:

University of Connecticut

Code:

NCT05283382

Conditions

Anxiety and Fear

Eligibility Criteria

Sex: All

Age: 18 - 50

Healthy Volunteers: Accepted

Interventions

Cannabidiol Oral Product

Placebo

Study Details

Brief summary:

To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose. Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined. It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.

Conditions

Anxiety and Fear

Study ID

NCT05283382

Start date

Oct 30, 2024

Status verified date

Apr, 2026

Completion date

Feb, 2027

Anticipated

Primary completion date

Dec 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 50

Healthy Volunteers: Accepted

Inclusion Criteria:

  • 18-50 years of age

Exclusion Criteria:

1. Difficulties seeing a computer screen
2. Anyone currently taking CBD within the last 24 hours.
3. Anyone using any cannabis product within the last 24 hours.
4. Heart problems or heart disease
5. A neurological disorder such as epilepsy, stroke, multiple sclerosis, tumor, vascular malformations, aneurysm
6. Are currently pregnant or breast-feeding

Study Design

Enrollment

160 participants

Anticipated

Allocation

Randomized

Intervention Model

Factorial

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Cannabidiol

600 mg Cannabidiol Isolate Gel Capsules / participant. One-time dose.

placebo comparator: Placebo

Same number of placebo capsules / participant. One-time dose.

Interventions

Cannabidiol Oral Product

Participants will receive a one-time dose of 600 mg Cannabidiol Isolate Gel Capsules in the form of six 100mg capsules.

Placebo

Participants will receive a one-time dose of placebo capsules in the form of six capsules.

Primary outcome measure

  • Electrodermal activity [ Time Frame: 20 minutes ]

Central Contacts and Locations

Central contacts

Locations

University of Connecticut

Recruiting

Storrs, Connecticut, United States, 06269-1020

Contacts

More Information

Sponsor

University of Connecticut

Last update posted

Apr 29, 2026

Last verified

Apr, 2026

Keywords

  • social anxiety
  • fear conditioning
  • cannabidiol
  • electrodermal response

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Connecticut on 2026-04-29.